

Automotive auction

Sector outlook



Jonathan Mardjuki

jonathan.mardjuki@clsa.com +62 21 5088 7815

Aimee Garibaldi

+62 21 5088 7837

Sarina Lesmina, CFA

+62 21 5088 7820

14 February 2022

Indonesia

Autos



Find CLSA research on Bloomberg, Thomson Reuters, FactSet and CapitallQ - and profit from our evalu@tor proprietary database at clsa.com

Online auction giant

Insights from automotive auction giant Autopedia (ASLC IJ)

Autopedia has seen growing traction in hybrid auctions in Indonesia amid Covid-19. Seizing the opportunity to be a market leader, management believes the ecosystem of its three business pillars – JBA, Caroline, and Cartalog – will be one of its key advantages to compete in the auction industry. The company believes that Caroline, the O2O marketplace for new and used cars, is set to be the future growth driver to double its sales in 2022.

Background of Autopedia

- □ Autopedia Sukses is an automotive auction company. Started in 2014 by providing offline car and motorcycle auctions through JBA BIDWIN, it has expanded into online car buying marketplace in 2019 amid Covid-19.
- Autopedia was recently listed on the IDX, raising c.Rp650bn of proceeds to be used for working capital and debt payment. The company is a subsidiary of Adi Sarana (ASSA IJ), which owns a 77.6% stake in Autopedia.

Autopedia business ecosystem

- One of Autopedia's key advantages is the ecosystem of its three business pillars: JBA BidWin Auction, Caroline, and Cartalog. It is the first company to have such integration.
- □ JBA is a hybrid auction with both offline and online marketplaces, for buying and selling used vehicles in major cities in Indonesia. There were 44k (+20% YoY) of 4W and 73k (+60% YoY) 2W sold in 2020. JBA is the largest auction player in Indonesia, with management stating it had 40% market share. The closest competitors is IBID, which is owned by conglomerate Astra Group.
- ☐ Management sees Caroline as set to be a future growth driver for Autopedia. It is an O2O automotive marketplace for both new and used cars. Users can buy and sell via its platform, Caroline.id. Caroline targets to sell 2,000 units in 2022.
- □ Cartalog is a car price engine with AI technology to provide fair pricing for all players in the automotive industry.

From offline to online and business model

- ☐ Management still sees domination of 'brick and mortar' or offline conventional auction in Indonesia. However, Covid-19 has led the way for a more hybrid auction model, in part due to social restrictions imposed by the government.
- □ Autopedia had its first online auction in 2020 under the JBAI application. There were 140k auction participants, with 50% already coming from online. This figure grew to 65% in 1H21.
- □ Autopedia could cater to various type of clients: individuals for Caroline; corporates (leasing companies and used car dealers) for Caroline and JBA; and sellers for JBA.
- ☐ There are about 10 auctions held every week, and 75% of the supply comes from corporate, with most buyers coming from dealers (B2B).

Expansion strategy

- Autopedia currently owns 35 networks of JBA nationwide from Java, Sumatra, and Kalimantan to Sulawesi, one of the largest in Indonesia.
- □ Caroline would be the next focus for expansion. The company plans to increase offline network of Caroline from 15 to 20 by the end of 2022.

Growth prospects in 2022

- ☐ Management is confident on growth prospect for auction business in Indonesia, with Caroline as the main growth driver for the company. It guides sales to reach Rp500bn in 2022, doubled from 2021. Auction business is expected to grow around 17% per year and Autopedia hopes to reach 100k units sold in five years.
- □ The company targets 10-15% sales growth in 2021, after +22% in 2020. Its 9M21 revenue came at Rp135bn, +3% YoY and 9M21 profit at Rp11bn (+40% YoY).
- ☐ Margins for Autopedia are 84% gross, 20% Ebit, and 8% net margin in 9M21. This is already the highest across other Adi Sarana's business segments ie, vehicle lease, logistics, or Anteraja.

www.clsa.com



Key charts

Figure 1

Autopedia business portfolio



Online and Offline Automotive Marketplace

ASLC established a used car auction business in mid 2014 called Bidwin. In 2019, the Company acquired 51% stake in JBA Indonesia and merged Bidwin's operation into the new the JBA Bidwin Auction ("JBA"). In 2021, the Company increased its stake to

Revenue model:

Source: ASLC

- Success fees from seller Administration fees from buyer Administration support fees from seller and buyer for longer terms of payment

CAROLINE

Online to Offline Used Car Dealers

Caroline engages in the buying and selling of used cars and new cars. It operates using both physical showrooms and online sales channels.

- Revenue model:
 Sale of inventory to end customers and also through auction channel
 Other income from financing and
- insurance partners Other income from additional services


CARTALOG

Price Engine & Listing

A car price engine that uses artificial intelligence technology to provide fair price to all players in the industry. Cartalog also provides listing service for used car dealers through its Cartalog


Figure 2

2W and 4Q sales trend in Indonesia




Source: Gaikindo, AISI


Autopedia's offline and online participants



Source: ASLC




Source: ASLC



Source: ASLC




Figure 6




Source: ASLC

Figure 8




Source: ASLC

Figure 10




Source: JBA

Figure 7




Source: ASSA

Figure 9



Source: ASSA

Figure 11



Source: Caroline.id





Research subscriptions

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email_alert/.


Companies mentioned

Adi Sarana (ASSA IJ - RP2,560 - BUY) Anteraja (N-R) Astra (ASII IJ - RP5,300 - O-PF) Autopedia (N-R) Bursa Efek Indonesia (N-R) Caroline.id (N-R) Cartalog (N-R) Ibid (N-R) JBA (N-R)

Analyst certification


The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.

Important disclosures



Source: CLSA





Date	Rec	Target	Date	Rec	Target
02 Nov 2021	O-PF	6,900.00	28 Apr 2020	U-PF	3,980.00
09 Aug 2021	BUY	6,100.00	02 Mar 2020	BUY	6,700.00
30 Nov 2020	O-PF	6,100.00	05 Aug 2019	O-PF	7,780.00
29 Jul 2020	SELL	4,500.00	06 Mar 2019	O-PF	8,100.00
10 Jun 2020	SELL	3,980.00			

Source: CLSA

CLSA ("CLSA") in this report refers to CLSA Limited, CLSA Americas, LLC, CLSA Australia Pty Ltd, CLSA India Private Limited, PT CLSA Sekuritas Indonesia, CLSA Securities Japan Co., Ltd., CLSA Securities Korea Ltd., CLSA Securities Malaysia Sdn. Bhd., CLSA Philippines, Inc, CLSA Singapore Pte Ltd, CLSA Securities (Thailand) Limited, CLSA (UK), CLSA Europe B.V. and/or their respective affiliates. CLST ("CLST") in this report refers to CL Securities Taiwan Co., Ltd.

The policies of CLSA and CLST are to only publish research that is impartial, independent, clear, fair, and not misleading. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out hereof and at www.clsa.com/disclaimer.html, the Conditions of Use as Terms set out at https://www.clsa.com/terms-and-conditions-of-use/ the and applicable regulation of the concerned market where the analyst is stationed and hence subject to. Investors are strongly encouraged to review this disclaimer before investing.

Neither analysts nor their household members or associates may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

(For full disclosure of interest for all companies mentioned in this report, please refer to http://www.clsa.com/member/research_disclosures/ for details.)

The analysts included herein hereby confirm that they have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts attest that they were not in possession of any material, non-public information regarding the subject company that has securities listed in the relevant jurisdiction(s) at the time of publication of this report. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this

report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, non-public information regarding the subject company that has securities listed in the relevant jurisdiction(s) at the time of publication of this report. The analysts further confirm that none of the information used in this report was received from CLSA's Corporate Finance department or CLSA's and/or CLST's Sales and Trading business. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

For the companies under research coverage, CLSA and/or CLST expect(s) to receive or intend(s) to seek compensation for investment banking services from Astra International Tbk in the next three months.

Key to CLSA/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF (aka ACCUMULATE): Total expected return below 20% but exceeding market return; U-PF (aka REDUCE): Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

"High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA (exclude CLST) only Universe: Overall rating distribution: BUY / Outperform - CLSA: 80.49%, Underperform / SELL - CLSA: 19.43%, Restricted - CLSA: 0.09%; Data as of 1 Jan 2022. Investment banking clients as a % of rating category: BUY / Outperform - CLSA: 13.41%, Underperform / SELL - CLSA: 1.92%; Restricted - CLSA: 0.09%. Data for 12-month period ending 1 Jan 2022.

Overall rating distribution for CLST only Universe: Overall rating



distribution: BUY / Outperform - CLST: 90.16%, Underperform / SELL - CLST: 9.84%, Restricted - CLST: 0.00%. Data as of 1 Jan 2022. Investment banking clients as a % of rating category: BUY / Outperform - CLST: 0.00%, Underperform / SELL - CLST: 0.00%, Restricted - CLST: 0.00%. Data for 12-month period ending 1 Jan 2022

There are no numbers for Hold/Neutral as CLSA/CLST do not have such investment rankings. For a history of the recommendation, price targets and disclosure information for companies mentioned in this report please write to: CLSA Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA estimates, "CT" stands for CLST estimates, "CRR" stands for CRR Research estimates and "CS" for Citic Securities estimates unless otherwise noted in the source.

Charts and tables sourced to CLSA in this report may include data extracted from CLSA's automated databases, which derive their original data from a range of sources. These can include: companies; analyst estimates/calculations; local exchanges and/or third-party data or market pricing providers such as Bloomberg, FactSet or IBES. Additional information on data sources for specific charts or tables can be obtained by contacting the publishing analysts.

This report is subject to and incorporates the terms and conditions use set out on the www.clsa.com website (https://www.clsa.com/disclaimer.html https://www.clsa.com/terms -and-conditions-of use/) and the references to "publication/communication" or "Publications" thereof shall include this report. Neither this report nor any portion hereof may be reprinted, sold, resold, copied, reproduced, distributed, redistributed, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of CLSA and/or CLST. CLSA and/or CLST has/have produced this report for private circulation to professional, institutional and/or wholesale clients only, and may not be distributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data (for private or public companies) herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and CLSA and/or CLST makes no representation or warranty as to its fairness, adequacy, accuracy, completeness or correctness. The replication of any third party views in this report should not be treated necessarily as an indication that CLSA and/or CLST agrees with or concurs with such views. None of CLSA and/or CLST, its affiliates and their respective directors, officers, employees, advisers and representatives makes any representation or warranty, express or implied, as to and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such data or information contained herein or any statement made in this report. Any opinions or estimates herein reflect the judgment of CLSA and/or CLST at the date of this report and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA and/or CLST. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

This report is for information purposes only and it does not constitute or contain, and should not be considered as an offer or invitation to sell, or any solicitation or invitation of any offer to subscribe for or purchase any securities in any jurisdiction and recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the

particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this report. you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including legal or tax advice. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Investments that are denominated in foreign currencies may fluctuate in value as a result of exposure to movements of exchange rate. Past performance is not necessarily a guide to future performance or liquidity. CLSA and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this report or its contents.

To maintain the independence and integrity of our research, our Corporate Finance, Sales Trading, Asset Management and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA's Corporate Finance department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance department nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management. CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading, Asset Management and Research activities. Some examples of these controls include: the use of information barriers and other controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance, Asset Management, and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's

Subject to any applicable laws and regulations at any given time, CLSA, CLST, their respective affiliates, officers, directors or employees may have used the information contained herein before publication and may have positions in, or may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided corporate finance/capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, you should be aware that CLSA and/or CLST and/or their respective affiliates, officers, directors or employees may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details are available at http://www.clsa.com/member/research_disclosures/. Disclosures therein include the position of CLSA and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subject company, covered in this report, or from any third party. If investors have any difficulty accessing this website, please contact webadmin@clsa.com on +852 2600 8111. If you require disclosure information on previous dates, please contact compliance hk@clsa.com.

Any disputes related to this report shall be governed by the laws of Hong Kong and to the non-exclusive jurisdiction of the courts of Hong Kong in connection with any suite, action or proceeding arising out of or in connection with this material. In the event any of the provisions in these Terms of Use shall be held to be unenforceable, that provision shall be enforced to the maximum extent permissible to reflect the intention underlying the unenforceable term, and the remainder of these General Disclaimer shall be unimpaired.

This report is distributed for and on behalf of CLSA (for research compiled by non-US and non-Taiwan analyst(s)), CLSA Americas, LLC



(for research compiled by US analyst(s)) and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd (ABN 53 139 992 331/AFSL License No: 350159); in Hong Kong by CLSA Limited (Incorporated in Hong Kong with limited liability); in India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; CIN: U67120MH1994PLC083118; Registration No: INZ000001735 as Stock Broker, INM000010619 as Merchant Banker and INH000001113 as Research Analyst; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd.; in Korea by CLSA Securities Korea Ltd.; in Malaysia by CLSA Securities Malaysia Sdn. Bhd.; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Singapore by CLSA Singapore Pte Ltd and solely to persons who qualify as an "Institutional Investor", "Accredited Investor" or "Expert Investor" MCI (P) 085/11/2021; in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST and in the European Economic Area ('EEA") by CLSA Europe BV and in the United Kingdom by CLSA (UK).

Australia: CLSA Australia Pty Ltd ("CAPL") (ABN 53 139 992 331/AFS License No: 350159) is regulated by ASIC and is a Market Participant of ASX Limited and CHI-X. This material is issued and distributed by CAPL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or particular needs of the recipient. The recipient of this material must not distribute it to any third party without the prior written consent of CAPL. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001. CAPL's research coverage universe spans listed securities across the ASX All Ordinaries index, securities listed on offshore markets, unlisted issuers and investment products which Research management deem to be relevant to the investor base from time to time. CAPL seeks to cover companies of relevance to its domestic and international investor base across a variety of sectors.

India: CLSA India Private Limited, incorporated in November 1994 provides equity brokerage services (SEBI Registration No: INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration No. INH000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking securities and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com.

Singapore: This report is distributed in Singapore by CLSA Singapore Pte Ltd to institutional investors, accredited investors or expert investors (each as defined under the Financial Advisers

Regulations) only. Singapore recipients should contact CLSA Singapore Pte Ltd, 80 Raffles Place, #18-01, UOB Plaza 1, Singapore 048624, Tel: +65 6416 7888, in respect of any matters arising from, or in connection with, the analysis or report. By virtue of your status as an institutional investor, accredited investor or expert investor, CLSA Singapore Pte Ltd is exempted from complying with certain requirements under the Financial Advisers Act (Chapter 110), the Financial Advisers Regulations and the relevant Notices and Guidelines issued thereunder (as disclosed in Part C of the Securities Dealing Services – Singapore Annex of the CLSA terms of business), in respect of any financial advisory services that CLSA Singapore Pte Ltd may provide to you. MCI (P) 085/11/2021

United States of America: Where any section of the research is compiled by US analyst(s), it is distributed by CLSA Americas, LLC. Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA (except CLSA Americas, LLC) solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas, LLC. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas, LLC.

The United Kingdom: this document is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The document is disseminated in the UK by CLSA (UK) and directed at persons having professional experience in matters relating to investments, as defined in the relevant applicable local regulations. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document. Where research material is compiled by UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules in the UK such material is prepared and intended as substantive research material. CLSA (UK) is authorised and regulated by the Financial Conduct Authority.

The European Economic Area ('EEA"): research is distributed by CLSA Europe BV, authorised and regulated by the Netherlands Authority for Financial Markets.

For all other jurisdiction-specific disclaimers please refer to https://www.clsa.com/disclaimer.html. The analysts/contributors to this report may be employed by any relevant CLSA entity or CLST, which is different from the entity that distributes the report in the respective jurisdictions.© 2022 CLSA and/or CL Securities Taiwan Co., Ltd. ("CLST").